Allogene Therapeutics ALLO Lessee Operating Lease Liability Undiscounted Excess Amount
Lessee Operating Lease Liability Undiscounted Excess Amount at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's lessee operating lease liability undiscounted excess amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's lessee operating lease liability undiscounted excess amount?
- Allogene Therapeutics (ALLO) reported lessee operating lease liability undiscounted excess amount of $21.64M in Q1 2026.
- How has Allogene Therapeutics's lessee operating lease liability undiscounted excess amount changed year-over-year?
- Allogene Therapeutics's lessee operating lease liability undiscounted excess amount decreased by 19.9% year-over-year, from $27.02M to $21.64M.